Jason Flamm
About
Jason Flamm is a scholar working on Infectious Diseases, Virology and Epidemiology.
According to data from OpenAlex, Jason Flamm has authored 36 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Infectious Diseases, 19 papers in Virology and 10 papers in Epidemiology. Recurrent topics in Jason Flamm's work include HIV/AIDS Research and Interventions (21 papers), HIV Research and Treatment (19 papers) and HIV/AIDS drug development and treatment (15 papers). Jason Flamm is often cited by papers focused on HIV/AIDS Research and Interventions (21 papers), HIV Research and Treatment (19 papers) and HIV/AIDS drug development and treatment (15 papers). Jason Flamm collaborates with scholars based in United States, United Kingdom and Italy. Jason Flamm's co-authors include Satya Dandekar, Sumathi Sankaran, Elizabeth Reay, Thomas Prindiville, Moraima Guadalupe, Andrew C. McNeil, Michael D. George, Mónica Macal, Jacob A. Wegelin and Barbara L. Shacklett and has published in prestigious journals such as Proceedings of the National Academy of Sciences, SHILAP Revista de lepidopterología and PLoS ONE.
In The Last Decade
Jason Flamm
35 papers receiving 2.1k citations
Hit Papers
Peers
Jason Flamm
Jason F. Okulicz United States
Huyen Cao United States
Henriëtte J. Scherpbier Netherlands
John P. Phair United States
Réjean Thomas Canada
Angela Meier United States
Melissa Krone United States
Sibyl P. M. Geelen Netherlands
Silvia Nozza Italy
Alessandro Cozzi‐Lepri United Kingdom
Citations per year, relative to Jason Flamm Jason Flamm (= 1×)
peers
Jason F. Okulicz
Countries citing papers authored by Jason Flamm
Since
Specialization
Citations
This map shows the geographic impact of Jason Flamm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jason Flamm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jason Flamm more than expected).
Fields of papers citing papers by Jason Flamm
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Jason Flamm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jason Flamm. The network helps show where Jason Flamm may publish in the future.
Co-authorship network of co-authors of Jason Flamm
This figure shows the co-authorship network connecting the top 25 collaborators of Jason Flamm. A scholar is included among the top collaborators of Jason Flamm based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jason Flamm. Jason Flamm is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Flamm, Jason, et al.. (2024). Digital bead modeling for wire-arc directed energy deposition. Journal of Manufacturing Processes. 129. 109–121.
2.
Satre, Derek D., Varada Sarovar, Amy Leibowitz, et al.. (2024). Factors associated with suicidal ideation among people with HIV engaged in care. Journal of Affective Disorders. 358. 369–376.
3.
Davy-Méndez, Thibaut, Varada Sarovar, Amy Leibowitz, et al.. (2023). Racial, ethnic, and age disparities in the association of mental health symptoms and polysubstance use among persons in HIV care. PLoS ONE. 18(11). e0294483–e0294483.
4.
Davy-Méndez, Thibaut, Amy Leibowitz, Andrea Altschuler, et al.. (2023). Mental health and substance use screening in HIV primary care before and during the early COVID-19 pandemic. BMC Health Services Research. 23(1). 494–494.
5.
Davy-Méndez, Thibaut, Varada Sarovar, Stacy Sterling, et al.. (2022). Characterizing Unhealthy Alcohol Use Patterns and Their Association with Alcohol Use Reduction and Alcohol Use Disorder During Follow-Up in HIV Care. AIDS and Behavior. 27(5). 1380–1391.
6.
Flamm, Jason, Cindy Garris, Ronald D’Amico, et al.. (2021). PB4 Patient Perspectives on Implementation of a Long-Acting Injectable Antiretroviral Therapy Regimen in HIV US Healthcare Settings: Final Month 12 Results from the CUSTOMIZE Study. Value in Health. 24. S13–S13.
7.
Park, Ina U., Jeffrey M. Schapiro, Leo B. Hurley, et al.. (2021). Improved Gonorrhea and Chlamydia Testing Among Men Who Have Sex With Men Living With HIV Through Implementation of Self-Collected Tests. Sexually Transmitted Diseases. 48(11). e165–e167.
8.
Silverberg, Michael J., Alexandra Anderson, Stacey Alexeeff, et al.. (2020). Health System‐Based Unhealthy Alcohol Use Screening and Treatment Comparing Demographically Matched Participants With and Without HIV. Alcoholism Clinical and Experimental Research. 44(12). 2545–2554.
9.
Satre, Derek D., Alexandra Anderson, Amy Leibowitz, et al.. (2019). Implementing electronic substance use disorder and depression and anxiety screening and behavioral interventions in primary care clinics serving people with HIV: Protocol for the Promoting Access to Care Engagement (PACE) trial. Contemporary Clinical Trials. 84. 105833–105833.
10.
Mills, Anthony, Gordon Crofoot, Cheryl McDonald, et al.. (2015). Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor–Based Single-Tablet Regimen for Initial HIV-1 Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes. 69(4). 439–445.
11.
Stellbrink, Hans‐Juergen, Andrea Antinori, Anton Pozniak, et al.. (2014). Switch to Stribild versus continuation of NVP or RPV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY‐NNRTI subgroup analysis. Journal of the International AIDS Society. 17(4S3). 19793–19793.
12.
Tebas, Pablo, Martin Fisher, Brian Gazzard, et al.. (2013). Efficacy of switching to rilpivirine/emtricitabine/tenofovir DF from boosted PI in HIV-1 virologically suppressed patients with or without the K103N. Journal of the International AIDS Society. 16(Suppl 1).
13.
Palella, Frank J., Martin Fisher, Pablo Tebas, et al.. (2013). Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants. AIDS. 28(3). 335–344.
14.
Sankaran‐Walters, Sumathi, Mónica Macal, Irina Grishina, et al.. (2013). Sex differences matter in the gut: effect on mucosal immune activation and inflammation. Biology of Sex Differences. 4(1). 10–10.
15.
Fourie, Jan, Jason Flamm, Peré Domingo, et al.. (2011). Effect of Baseline Characteristics on the Efficacy and Safety of Once-Daily Darunavir/ Ritonavir in HIV-1–Infected, Treatment-Naïve ARTEMIS Patients at Week 96. HIV Clinical Trials. 12(6). 313–322.
16.
Guadalupe, Moraima, Richard Donovan, Jason Flamm, et al.. (2011). The Gut Mucosal Viral Reservoir in HIV-Infected Patients Is Not the Major Source of Rebound Plasma Viremia following Interruption of Highly Active Antiretroviral Therapy. Journal of Virology. 85(10). 4772–4782.
17.
Mitsuya, Yumi, Mark A. Winters, W. Jeffrey Fessel, et al.. (2006). HIV-1 Drug Resistance Genotype Results in Patients With Plasma Samples With HIV-1 RNA Levels Less Than 75 Copies/mL. JAIDS Journal of Acquired Immune Deficiency Syndromes. 43(1). 56–59.
18.
Ashton, E. H., Mark A. Vosvick, Margaret A. Chesney, et al.. (2005). Social Support and Maladaptive Coping as Predictors of the Change in Physical Health Symptoms among Persons Living with HIV/AIDS. AIDS Patient Care and STDs. 19(9). 587–598.
19.
Belanoff, Joseph K., Cheryl Koopman, Christine Blasey, et al.. (2005). A Randomized Trial of the Efficacy of Group Therapy in Changing Viral Load and CD4 Counts in Individuals Living with HIV Infection. The International Journal of Psychiatry in Medicine. 35(4). 349–362.
20.
Rhee, Soo‐Yon, W. Jeffrey Fessel, Andrew Zolopa, et al.. (2005). HIV‐1 Protease and Reverse‐Transcriptase Mutations: Correlations with Antiretroviral Therapy in Subtype B Isolates and Implications for Drug‐Resistance Surveillance. The Journal of Infectious Diseases. 192(3). 456–465.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Jason F. Okulicz Breakdown of academic impact, for papers by Huyen Cao Breakdown of academic impact, for papers by Henriëtte J. Scherpbier Breakdown of academic impact, for papers by John P. Phair Breakdown of academic impact, for papers by Réjean Thomas Breakdown of academic impact, for papers by Angela Meier Breakdown of academic impact, for papers by Melissa Krone Breakdown of academic impact, for papers by Sibyl P. M. Geelen Breakdown of academic impact, for papers by Silvia Nozza Breakdown of academic impact, for papers by Alessandro Cozzi‐Lepri